The Asia Pacific Ovulation Testing Kits Market would witness market growth of 7.1% CAGR during the forecast period (2023-2030). In the year 2021, the Asia Pacific market's volume surged to 1,43,859.2 thousand units, showcasing a growth of 5.4% (2019-2022).
Educational initiatives, social media campaigns, and influencers in the field of fertility have contributed to this rising awareness, encouraging more women to use ovulation testing kits. Ovulation testing kit manufacturers are increasingly offering customization and personalization options. Some kits allow users to input their unique cycle data for more accurate predictions, catering to the diverse needs of women with varying menstrual cycles. The market has seen significant expansion in terms of geographic reach. Ovulation testing kits are becoming more accessible in emerging markets, where rising disposable incomes and changing lifestyles have led to increased interest in family planning and fertility health.
Ovulation testing kits play a crucial role in family planning by helping couples identify the woman's fertile window. By pinpointing the days when ovulation is most likely to occur, these kits allow couples to time their intercourse for the highest chances of conception. In addition, the increasing prevalence of polycystic ovary syndrome (PCOS) is another factor that has led to market growth. PCOS is a common hormonal disorder that often leads to irregular ovulation. Furthermore, the increasing number of women facing fertility issues, particularly those with PCOS actively seeking to conceive, is expected to increase the demand for ovulation testing.
According to the National Library of Medicine, the infertility rate in India was between 15 and 20 million (25%) in 2019. Likewise, in Japan, 18.2% of couples have either undergone or are undergoing infertility testing or treatment, that is 1 in 5.5 of all couples. With the growing number of infertilities, the market is expected to expand significantly in this nation. As fertility health and family planning become more significant in Asia-Pacific, the market is expected to grow. Manufacturers and healthcare providers will likely adapt to the specific demands and preferences of customers in APAC countries, further fueling the growth of this market. The aforementioned factors will expand the market growth across the region in the coming years.
The China market dominated the Asia Pacific Ovulation Testing Kits Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $287.5 million by 2030. The Japan market is registering a CAGR of 6.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 7.7% during (2023 - 2030).
Based on Product, the market is segmented into Urine Ovulation Test, Digital Ovulation Test, and Saliva Ovulation Test. Based on Distribution Channel, the market is segmented into Pharmacies & Drugstores, Hypermarkets & Supermarkets, and E-Commerce. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AccuQuik Testkits (AdvaCare Pharma), Fairhaven Health, LLC, Equinox Biotech Co., Ltd., Wondfo Biotech Co., Ltd, Pregmate, SPD Swiss Precision Diagnostics GmbH, Proov, Roman Health Ventures Inc. (Ro), Premom (Easy@Home Fertility), and Piramal Enterprises Limited.
Educational initiatives, social media campaigns, and influencers in the field of fertility have contributed to this rising awareness, encouraging more women to use ovulation testing kits. Ovulation testing kit manufacturers are increasingly offering customization and personalization options. Some kits allow users to input their unique cycle data for more accurate predictions, catering to the diverse needs of women with varying menstrual cycles. The market has seen significant expansion in terms of geographic reach. Ovulation testing kits are becoming more accessible in emerging markets, where rising disposable incomes and changing lifestyles have led to increased interest in family planning and fertility health.
Ovulation testing kits play a crucial role in family planning by helping couples identify the woman's fertile window. By pinpointing the days when ovulation is most likely to occur, these kits allow couples to time their intercourse for the highest chances of conception. In addition, the increasing prevalence of polycystic ovary syndrome (PCOS) is another factor that has led to market growth. PCOS is a common hormonal disorder that often leads to irregular ovulation. Furthermore, the increasing number of women facing fertility issues, particularly those with PCOS actively seeking to conceive, is expected to increase the demand for ovulation testing.
According to the National Library of Medicine, the infertility rate in India was between 15 and 20 million (25%) in 2019. Likewise, in Japan, 18.2% of couples have either undergone or are undergoing infertility testing or treatment, that is 1 in 5.5 of all couples. With the growing number of infertilities, the market is expected to expand significantly in this nation. As fertility health and family planning become more significant in Asia-Pacific, the market is expected to grow. Manufacturers and healthcare providers will likely adapt to the specific demands and preferences of customers in APAC countries, further fueling the growth of this market. The aforementioned factors will expand the market growth across the region in the coming years.
The China market dominated the Asia Pacific Ovulation Testing Kits Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $287.5 million by 2030. The Japan market is registering a CAGR of 6.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 7.7% during (2023 - 2030).
Based on Product, the market is segmented into Urine Ovulation Test, Digital Ovulation Test, and Saliva Ovulation Test. Based on Distribution Channel, the market is segmented into Pharmacies & Drugstores, Hypermarkets & Supermarkets, and E-Commerce. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AccuQuik Testkits (AdvaCare Pharma), Fairhaven Health, LLC, Equinox Biotech Co., Ltd., Wondfo Biotech Co., Ltd, Pregmate, SPD Swiss Precision Diagnostics GmbH, Proov, Roman Health Ventures Inc. (Ro), Premom (Easy@Home Fertility), and Piramal Enterprises Limited.
Scope of the Study
Market Segments Covered in the Report:
By Product (Volume, Thousand Units, USD Million, 2019-2030)- Urine Ovulation Test
- Digital Ovulation Test
- Saliva Ovulation Test
- Pharmacies & Drugstores
- Hypermarkets & Supermarkets
- E-Commerce
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- AccuQuik Testkits (AdvaCare Pharma)
- Fairhaven Health, LLC.
- Equinox Biotech Co., Ltd
- Wondfo Biotech Co., Ltd
- Pregmate
- SPD Swiss Precision Diagnostics GmbH
- Proov
- Roman Health Ventures Inc. (Ro)
- Premom (Easy@Home Fertility)
- Piramal Enterprises Limited
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Ovulation Testing Kits Market, by Product
Chapter 5. Asia Pacific Ovulation Testing Kits Market, by Distribution Channel
Chapter 6. Asia Pacific Ovulation Testing Kits Market, by Country
Chapter 7. Company Profiles
Companies Mentioned
- AccuQuik Testkits (AdvaCare Pharma)
- Fairhaven Health, LLC.
- Equinox Biotech Co., Ltd
- Wondfo Biotech Co., Ltd
- Pregmate
- SPD Swiss Precision Diagnostics GmbH
- Proov
- Roman Health Ventures Inc. (Ro)
- Premom (Easy@Home Fertility)
- Piramal Enterprises Limited
Methodology
LOADING...
